Explore the Agenda

7:00 am Check In & Morning Coffee

7:50 am Chair’s Opening Remarks

Strengthening the Scientific & Commercial Foundations for Next-Generation mRNA Therapeutics

8:00 am Panel Discussion: Positioning mRNA Programmes to Attract Investment & Strategic Partnerships

Senior Director Business Development, Ethris GmbH
Chief Executive Officer, Abogen Biosciences
Chief Executive Officer, Pantherna Therapeutics
  • Addressing investor expectations: balancing early-stage innovation with clinical validation requirements
  • Understanding how political & regulatory headwinds impact RNA therapeutic investment (vaccine hesitancy, government funding changes)
  • Navigating the tension between long-term scientific development & short-term investor exit timelines

Engineering & Evaluating mRNA Delivery Systems to Improve Therapeutic Performance

8:45 am Advancing Extrahepatic RNA Delivery Through Modular Peptide-Based Nanoparticles for Emerging Therapeutic Applications

Chief Operating Officer, Altamira Therapeutics
  • Enabling extrahepatic delivery to the tumour microenvironment using peptide-based nanoparticles
  • Optimising the modularity and flexibility of peptide-based delivery systems to improve tissue selectivity and expand targeting capabilities
  • Evaluating emerging oncology applications of non-viral delivery platforms, including preclinical approaches to assessing therapeutic performance and tissue distribution

Right click on the image to save it to your computer.

9:15 am Session Reserved for Roche

9:25 am Advanced Nanoparticle Characterisation & Tissue-Level Models to Improve Therapeutic Performance

Professor of Biochemistry, Group Leader Targeted Nanomedicines, Radboud University Medical Center
  • Evaluating how LNP composition and targeting strategies influence biodistribution, cellular uptake and off-target exposure across preclinical models
  • Improving peptide-based nanoparticle activity through formulation optimisation, using cryo-electron microscopy (cryo-EM) to understand particle morphology and structure-activity relationships
  • Investigating endosomal escape and cellular trafficking using quantitative livecell microscopy to understand how nanoparticle structure influences transfection efficiency
  • Leveraging tissue-on-a-chip models to evaluate nanoparticle penetration, tissue retention and cell-specific transfection before progressing into animal studies

Right click on the image to save it to your computer.

Right click on the image to save it to your computer.

10:00 am Morning Break & Networking

RESEARCH & PRECLINICAL DEVELOPMENT

Advancing Alternative Carriers & Targeted LNP Technologies for Cell & Tissue-Specific RNA Delivery

11:00 am Enabling Tissue- & Cell-Specific mRNA Delivery with Cell-Penetrating Peptide-Based Hybrid Nanosystems

Prof of Molecular Medicine, University of Tartu
  • Optimising cell-penetrating peptides and hybrid nanoparticle- RNA interactions to achieve stable complexation, cellular uptake & intracellular cargo release
  • Engineering peptide-based systems for selective delivery to specific tissues or cell populations
  • Comparing targeting performance, tolerability, scalability & manufacturability against established LNP platforms
  • Identifying applications where alternative delivery vehicles can provide a meaningful targeting or therapeutic advantage over LNPs

Right click on the image to save it to your computer.

Right click on the image to save it to your computer.

11:30 am Developing Cell-Specific or Organ-Specific Delivery Using Targeting Ligands & Surface Modifications to Avoid Off-Target Toxicity

Founding Scientist, Nanograb
  • Leveraging biophysics-informed AI to design combinations of peptide binders for cell-specific LNP targeting, moving beyond conventional single-receptor approaches
  • Conjugating targeting moieties such as ligands, antibodies & short linear peptides to LNP surfaces to achieve cell-specific or tissue-specific delivery
  • Developing scalable, multi-peptide LNP targeting strategies to enable extrahepatic mRNA delivery across different cell types and therapeutic applications

Right click on the image to save it to your computer.

Right click on the image to save it to your computer.

PROCESS DEVELOPMENT & CMC

Aligning Analytical, Quality & CMC Strategies with Emerging RNA Therapeutic Requirements

11:00 am Developing Analytical & Potency Assays That Connect Product Quality to Biological Function

Director CMC, Epitopea Ltd
  • Sharing learnings of how preclinical data can link to clinical functionality
  • Exploring how different RNA therapeutics have different assumptions on clinical functionality and how to translate that into assays (e.g. personalised vs gene replacement etc.)
  • Incorporating these considerations early in the preclinical thought process and early-stage clinical development
  • Differentiating mode-of-action assays from simple protein expression readouts: demonstrating clinical relevance

Right click on the image to save it to your computer.

11:30 am Adapting CMC & Quality by Design for Individualised mRNA-LNP Therapies

Associate Director GMP/CMC Drug Product, BioNTech
  • Applying phase-appropriate CMC strategies to enable the efficient development and clinical translation of individualised mRNA-LNP therapies
  • Leveraging Quality by Design (QbD) principles to build product and process understanding while maintaining flexibility for patient-specific treatments
  • Addressing comparability, control strategy, and regulatory considerations in the evolving landscape of personalised medicines

12:00 pm Lunch & Networking

Aligning Expression Duration, Dosing and Administration Strategies with Therapeutic Needs to Reduce Patient Burden

1:00 pm Long-acting xRNA for Durable, Combination Peptide Therapy in Chronic Metabolic Disease

Vice President, Discovery, ScionxBio
  • The modality: xRNA, a chemically modified long-acting RNA encoding protein and peptides, with durability designed in rather than added by the dosing schedule
  • Durability: single-dose expression sustained for weeks; in NHP, peptide and RNA still present at ~25 days, pointing to a dosing interval of around a month
  • Combination by design: multiple single-payload xRNA molecules combined at a defined, adjustable ratio and delivered as one product
  • Preclinical efficacy: the four-molecule multi-agonist improved weight, glucose and liver function in obesity and MASH models, beating single and triple agonists and, weekly, daily semaglutide
  • Takeaway: long-acting xRNA turns encoded peptides into durable, combination cardio-metabolic therapies

Right click on the image to save it to your computer.

1:30 pm Advancing Durable In Vivo CAR-T Cell Engineering Through Non-Viral DNA & mRNA Co-Delivery

Vice President, Strategy & Development, CPTx
  • Optimising co-encapsulation of single-stranded DNA and mRNA within targeted lipid nanoparticles to enable efficient delivery of both nucleic acids into the same cell
  • Leveraging single-stranded DNA to address immunogenicity challenges associated with conventional double-stranded DNA delivery while enabling more durable genetic modification
  • Demonstrating the flexibility of non-viral genome engineering through site-specific gene integration and multi-gene delivery strategies, supported by preclinical therapeutic data

Right click on the image to save it to your computer.

2:00 pm Advancing RNA Nanomedicine for Delivery to Challenging Tissues: Focus on the Lung

Full Professor of Pharmaceutical Technology, University of Naples Federico
  • Designing polymeric nanocarriers for the delivery of RNA therapeutics to treat complex respiratory diseases
  • Exploring nebulizer-based delivery strategies for RNA therapeutics and targeted local delivery to the lung
  • Advancing the manufacturing of inhalable RNA nanomedicines from the lab toward clinical-scale production

Right click on the image to save it to your computer.

Right click on the image to save it to your computer.

Prioritising CMC Investments & Manufacturing Strategies to Support Scalable RNA Development

1:00 pm Emerging Biotech Peer Exchange: Building CMC Strategies with Limited Resources

Director CMC, Epitopea Ltd

For emerging RNA developers, deciding where to invest limited CMC resources can be just as challenging as the technical development itself.

Designed as an informal, networking session, this peer exchange offers early-stage biotech teams the opportunity to connect with others facing similar challenges, share lessons learned and exchange practical advice in an open, collaborative setting.

An interactive discussion for early-stage mRNA developers to compare how they are:

  • Deciding when to invest in internal CMC capabilities versus external support
  • Prioritising spend across process development, assay development and regulatory preparation
  • Selecting CDMOs and consultants that understand the needs of smaller companies
  • Avoiding early development decisions that create expensive problems later

2:00 pm Building Continuous & Modular mRNA Manufacturing Platforms to Improve Flexibility, Contamination Control & Cost Efficiency

Research Associate, University of Sheffield
  • Using closed systems to reduce contamination risk and manual intervention
  • Building modular IVT, purification and LNP manufacturing operations that can flex between products and scales
  • Standardising equipment and process controls to simplify transfer between manufacturing sites
  • Understanding where modular manufacturing genuinely improves cost, speed and flexibility versus traditional fixed facilities

Right click on the image to save it to your computer.

Right click on the image to save it to your computer.

2:30 pm Afternoon Break & Networking

Shaping the Next Generation of mRNA Therapeutics Through Emerging Modalities & High- Value Clinical Applications

3:00 pm Employing circRNA Durability to Sustain Therapeutic Protein Expression in Fibrosis

Chief Executive Officer, Circurna
  • Demonstrating sustained circRNA-driven protein and peptide expression in fibrosis to explore where greater durability can reduce repeat administration and improve therapeutic effect
  • Leveraging microneedle patch delivery into the dermis to generate strong immune responses at lower RNA doses while enabling simpler, potentially at-home administration
  • Comparing circRNA with conventional linear mRNA across therapeutic and vaccine applications to understand how expression duration, dose and route of administration translate into reduced treatment burden

Right click on the image to save it to your computer.

3:30 pm Harnessing circRNA Stability to Increase Expression, Reduce Dose & Expand into In Vivo CAR-T

Vice President of Research, Circio AB
  • Potent, durable expression – circVec harnesses the intrinsic stability of circular RNA to accumulate transcripts intracellularly, delivering more protein per vector and sustaining expression far longer than conventional mRNA-based systems
  • Dose-sparing AAV gene therapy – by amplifying expression per vector genome, circVec enables robust therapeutic output at substantially lower AAV doses, with dose reduction demonstrated in both heart and eye – offering the potential to widen the therapeutic window and reduce dose-related toxicity
  • Expanding in vivo CAR-T using targeted LNPs and cell-specific expression to improve immune-cell targeting

4:00 pm Panel Discussion: Defining the Most Valuable Use Cases for mRNA-LNP Therapeutics: Prioritising Applications with the Greatest Clinical & Commercial Potential

Vice President Technology Profiling, BioNTech
Chief Executive Officer, Divincell
Chief Executive Officer, Pantherna Therapeutics
Principal Investigator, Project Leader, Almirall
  • Identifying “sweet spots” for mRNA-LNP therapeutics based on dosing frequency, administration route & immune considerations
  • Focusing development on validated applications: Cancer vaccines, infectious disease vaccines, protein replacement & in vivo CAR-T
  • Learning from clinical setbacks to understand biological & commercial limitations of the platform

4:45 pm Chair’s Closing Remarks

4:50 pm End of Conference Day Two